## Edgar Filing: Dicerna Pharmaceuticals Inc - Form 4

	rmaceuticals Inc										
Form 4	-										
June 16, 2017 FORM 4 LINUTED STATES SECURITIES AND EXCHANCE COMMISSION								OMB APPROVAL			
	Check this box							OMB Number:	3235-0287 January 31,		
if no long subject to Section 1 Form 4 o Form 5	Section	NGES IN SECUF	Expires: 2 Estimated average burden hours per response								
obligation may cont <i>See</i> Instru 1(b).	inue. Section 17			Itility Hol	•	- ·	ct of 1935 or Section f 1940	n			
(Print or Type I	Responses)										
1. Name and Address of Reporting Person <u>*</u> ROSSKAMP RALF			2. Issuer Name <b>and</b> Ticker or Trading Symbol Dicerna Pharmaceuticals Inc [DRNA]				Issuer	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
							(Chec				
				of Earliest T Day/Year) 2017	ransaction		Director X Officer (give below) Chief		% Owner ler (specify er		
				endment, Day/Yea	-	ıl	Applicable Line)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
CAMBRID	GE, MA 02140						Form filed by M Person	Iore than One R	eporting		
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivative	Securities	s Acquired, Disposed of	f, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)			3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or			SecuritiesFBeneficially(JOwned(J	orm: Direct D) or Indirect			
				Code V	Amount	(D) Prie	ce (instr. 5 and 4)				
Reminder: Rep	ort on a separate line	e for each cl	ass of sec	urities benef	ficially ow	ned directl	y or indirectly.				

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. 3. Transaction Dat Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of tiorDerivative Securities ) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares		
Employee Stock Option (Right to Buy)	\$ 2.91	06/15/2017		А	250,000		<u>(1)</u>	06/15/2027	Common Stock	250,00		
Reporting Owners												
<b>Reporting Owner Name / Address</b>			Relationships									
			Director	10% Ow	ner Office	er		Other				
ROSSKAMP RALF C/O DICERNA PHARMACEUTICALS, II 87 CAMBRIDGEPARK DRIVE CAMBRIDGE, MA 02140			S, INC.	Chief Medical Officer								
Signat	ures											
/s/ John B. attorney-in	· · · · · · · · · · · · · · · · · · ·		06/16/2017									

## Edgar Filing: Dicerna Pharmaceuticals Inc - Form 4

\*\*Signature of Reporting Person

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Date

The option vests 25% on the first year anniversary of the vesting start date of June 15, 2017 and the remaining 75% vests in 36

(1) substantially equal monthly installments thereafter, subject in each case to the reporting person's continued employment with the issuer through the applicable vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.